GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
© 2024 Brokerscompare.co | All Rights Reserved
Disclaimer: Brokerscompare.co offers evaluations, insights, and reports on financial markets and investment products. We do not provide brokerage services nor can we promise specific financial outcomes. Every investment carries risk, including the potential loss of invested capital. The material on this website is intended for informational use only and should not be interpreted as professional financial advice. Outcomes may differ, and it’s important to seek guidance from a licensed financial advisor before making any investment decisions.
Risk Warning
Trading in financial markets, including currencies, carries a high level of risk and may result in the loss of your capital. Price fluctuations may occur due to factors such as market volatility, regulatory updates, or political events. Past performance is not a reliable indicator of future results.
Content Usage Restrictions
No portion of this website or its materials may be copied, shared, or distributed in any manner without express written consent from Brokerscompare.co.
R Media LTD, Unit 1603, 16th Floor, The L. Plaza, 367-375 Queen’s Road Central, Sheung Wan, Hong Kong
powered by MNN Srl – PI/CF 05374430261 – Piazza della Serenissima 60, 31033 Castelfranco Veneto (TV) – © All rights reserved 2023